Capital Allocation

Capital Allocation

Zoetis returned $4.1 billion to shareholders in 2025 — about 1.8 times free cash flow — funding the gap with a new $2.0 billion convertible and $1.85 billion of senior notes. The buyback has shrunk the share count roughly 9% since 2022, but at average prices of $136 to $178, well above the ~$76 the stock reached in 2026. Directors and officers own under 1% of the company; there is no founder. Governance screens clean, and three directors bought at the lows.

A capital-return surge that outran cash

Zoetis is a distributor of its own cash. It carries no acquisition ambition large enough to absorb the roughly $2.3 billion of free cash flow the business throws off, so almost all of it goes back to shareholders through buybacks and a growing dividend (Cash Conversion). In most years that return has run close to, or just above, free cash flow. In 2025 it broke away from it.

Buyback and dividend cash from the FY2025 cash flow statement; free cash flow derived as operating cash flow less capital expenditure [1].

Total returns rose from about $1.78 billion in 2023 (1.10x free cash flow) to $2.64 billion in 2024 (1.15x) to $4.12 billion in 2025 — 1.81 times the $2.28 billion of free cash flow the company generated that year [1]. The company covered the shortfall by raising debt: it issued $2.0 billion of convertible notes and $1.85 billion of senior notes during the year, against $1.35 billion repaid, and long-term debt rose from $5.22 billion to $9.04 billion [1][2]. This is the year management chose to lean into the buyback as the stock fell, rather than let repurchases float with cash generation.

The buyback's price problem

The instinct — buy more as the price drops — is the right one. The execution has been costly. Zoetis has repurchased shares every year, and the pace accelerated: 6.3 million shares for $1.10 billion in 2023, 10.5 million for $1.87 billion in 2024, and 23.9 million for $3.25 billion in 2025 [3]. But the average price paid in each of those years sits above where the stock later traded.

Average price derived from treasury shares acquired and cash paid, FY2025 10-K equity statement; recent price is the July 2026 market level [3].

The 2023 and 2024 tranches averaged roughly $175 and $178 a share; the 2025 tranche, bought into the decline, averaged about $136 [3]. All three are well above the ~$76 at which the shares traded in mid-2026 after the guidance cut (The De-Rating). Judged against the price today, more than $6 billion of buybacks over three years bought shares the market now values at roughly half. That is the plain counter to any claim of counter-cyclical discipline: management bought steadily on the way down, not at the bottom.

The offsetting facts are real and worth stating. The repurchases did reduce shares outstanding from about 464 million at the end of 2022 to 425 million at the end of 2025 — a ~9% cut that lifts per-share earnings and concentrates each holder's claim [2]. Diluted earnings per share reached $6.02 in 2025, and the dividend has risen every year, from $1.56 per share declared in 2023 to $2.03 in 2025 [4]. What would change the read on the buyback is time: if the business reaccelerates and the shares recover, the 2025 purchases look astute; if the de-rating proves structural, they will read as debt raised to support a falling stock.

The convertible and the capped call

The instrument that funded the 2025 acceleration deserves its own look, because it is where financial engineering meets the buyback. In December 2025 Zoetis issued $2.0 billion of convertible senior notes due 2029 at a coupon of just 0.250%, with an initial conversion price of about $148.20 per share [5]. Of the $1.97 billion of net proceeds, $248 million bought back 2.1 million shares concurrently — implying a share price near $118 at issuance — and a further $1.54 billion funded additional repurchases, substantially completed by year-end [5].

The mechanics favour shareholders in two ways. The 0.250% coupon is close to free money — about $5 million of annual interest on $2.0 billion — so the trade swaps expensive equity for very cheap debt. And Zoetis spent $187 million on capped call transactions that lift the effective conversion price the company would bear from $148.20 to $211.72, covering roughly 13.5 million shares, so dilution is neutralised unless the stock nearly triples from today [5]. Bondholders, in exchange for the low coupon, hold a call struck at $148.20 — nearly double the mid-2026 price — so conversion only becomes a live question if the shares recover substantially.

The judgment is mixed rather than damning. The structure is a sophisticated, low-cost way to retire equity, and the capped call genuinely limits future dilution. But it added $2.0 billion of permanent-feeling debt to accelerate a buyback whose timing has, so far, been poor — and the $187 million spent on the capped call is a real cash cost paid to protect against a dilution scenario that requires the stock to almost triple. A company this cash-generative did not need to borrow to return capital; it chose to.

Solvency: the bankruptcy line

For a reader who never touches a company that could go bankrupt, the debt build warrants a direct check, and it clears comfortably. Zoetis ended 2025 with about $9.2 billion of unsecured debt against $2.31 billion of cash, an undrawn $1.25 billion revolving facility, and an undrawn $1.0 billion commercial paper program [6]. Net debt sits around 1.6 times EBITDA, against a credit-facility covenant ceiling of 3.50 times, and pre-tax interest of $222 million is covered about 16 times by pre-tax profit [4].

Source: FY2025 Annual Report (Form 10-K), long-term debt maturity table [7].

Nothing matures in 2026, and the ladder is spread out to 2050, with the largest single maturity being the $2.0 billion convertible in 2029 [7]. The coupons are mostly low and fixed. Against a business that converts profit to cash at a high rate, this is an investment-grade balance sheet used more aggressively than before, not a stressed one. The bankruptcy exclusion is not triggered; the more apt concern is that leverage has been spent on buybacks rather than kept as dry powder.

Who owns Zoetis

On the reader's insider-ownership question, the answer is unambiguous and modest. As of March 2026, all current directors and executive officers as a group — 22 people — held 912,848 shares, which the proxy confirms is under 1% of the 420.6 million shares outstanding [8]. Chief Executive Kristin Peck's beneficial holding of 492,586 shares is mostly exercisable options; her directly held common stock is about 106,000 shares — a fraction of a single year of her compensation [8]. There is no founder and no family block. The largest holders are index managers: Vanguard at 11.4% and BlackRock at 8.7% [9].

That thin insider stake is the honest weakness for an investor who prizes owner-operators. It is partly offset by what insiders did with their own money as the stock fell. In May 2026, with the shares in the mid-$70s, three directors bought in the open market.

Source: SEC Form 4 filings, open-market purchases dated May 11–13, 2026.

The three purchases totalled about $886,000 — small against a $32 billion company, but they are open-market buys with personal cash near the lows, not grants, and they came from the non-executive chairman and two long-tenured directors, including Frank D'Amelio, Pfizer's former chief financial officer. Insider selling in the period was routine option-exercise and tax-withholding activity, not discretionary exits. The signal is limited by size, but it points the right way.

Governance and the founder-CEO question

Against the reader's standard that weak governance is a reason to walk away, Zoetis screens clean. The board has 12 directors, 11 of them independent; the only non-independent member is the CEO [10]. The roles of chair and chief executive are separated, with Michael McCallister, former Humana CEO, serving as non-executive chairman. Directors stand for election annually, and there is a single class of stock — one share, one vote — so no insider controls the company through structure. CEO pay of $19.0 million in 2025, a 236-to-1 ratio to the median employee, is ordinary for a large-cap pharmaceutical, with about 70% delivered in stock and options that tie it to the share price [11]. None of the usual red flags — dual-class control, a stale board, entrenchment devices, related-party enrichment — are present.

This is where the reader's preference for a founder CEO who personally fronts quarterly calls meets a company that only half-fits it. On the quarterly-call half, Zoetis fits well: Peck leads earnings calls herself, and the company has a deep, consistent record of quarterly disclosure and investor engagement. On the founder half, it does not fit at all. Zoetis was carved out of Pfizer and taken public in 2013; Peck is a professional manager who has run the business since January 2020, not an owner-founder, and the insider group owns under 1%.

Set the founder preference aside, and the case for this structure is stronger than it first looks. A carve-out mega-cap with a genuinely independent board, an independent chair, annual elections, one-share-one-vote, and heavily equity-weighted pay is, on most governance measures, better protected than a founder-controlled company where a single holder can override minority shareholders. Alignment here does not come from a founder's stake; it comes from board independence, compensation tied to the share price, and — as the May 2026 buying shows — directors willing to put personal capital in at the lows. The legitimate residual concern is narrow and specific: with so little insider equity, the buyback and leverage decisions of the past two years rest on the board's judgment and the incentive design, not on a large owner feeling the loss alongside outside holders. That is exactly the kind of decision where a founder's skin in the game would have mattered most — and where, so far, the results argue for keeping management honest with evidence rather than trust.